Ticker
BMY

Price
71.50
Stock movement down
-0.92 (-1.27%)
Company name
Bristol-Myers Squibb Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
152.23B
Ent value
211.25B
Price/Sales
3.24
Price/Book
4.81
Div yield
3.02%
Div growth
5.22%
Growth years
12
FCF payout
29.54%
Trailing P/E
24.27
Forward P/E
8.89
PEG
1.32
EPS growth
10.90%
1 year return
4.35%
3 year return
15.35%
5 year return
4.39%
10 year return
8.52%
Last updated: 2022-08-25

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.16
Dividend yield3.02%
Payout frequencyQuarterly
Maximum yield4.03%
Average yield3.05%
Minimum yield2.32%
Discount to avg yield-1.10%
Upside potential-1.09%
Yield as % of max yield75.01%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.02%
Current yield distribution53.17%
Yield at 100% (Min)2.32%
Yield at 90%2.59%
Yield at 80%2.80%
Yield at 50% (Median)3.04%
Yield at 20%3.33%
Yield at 10%3.52%
Yield at 0% (Max)4.03%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share2.16
Payout frequencyQuarterly
Ex-div date30 Jun 2022
EPS (TTM)2.83
EPS (1y forward)8.04
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR10.20%15.44%
DGR TTM9.90%7.80%
DGR 3 years-2.79%3.88%
DGR 5 years5.22%4.73%
DGR 10 years1.08%8.30%
DGR 15 years1.83%5.82%
Time since last change announced293 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM71.33%29.54%
Average--
Forward26.87%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E24.27
Price to OCF9.40
Price to FCF10.05
Price to EBITDA8.22
EV to EBITDA11.41

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.24
Price to Book4.81
EV to Sales4.50

FINANCIALS

Per share

Loading...
Per share data
Current share count2.13B
EPS (TTM)2.83
FCF per share (TTM)6.82

Income statement

Loading...
Income statement data
Revenue (TTM)46.96B
Gross profit (TTM)37.39B
Operating income (TTM)10.64B
Net income (TTM)6.27B
EPS (TTM)2.83
EPS (1y forward)8.04

Margins

Loading...
Margins data
Gross margin (TTM)79.62%
Operating margin (TTM)22.65%
Profit margin (TTM)13.35%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash12.37B
Net receivables8.51B
Total current assets30.12B
Goodwill20.50B
Intangible assets40.10B
Property, plant and equipment0.00
Total assets103.03B
Accounts payable2.94B
Short/Current long term debt44.97B
Total current liabilities22.82B
Total liabilities71.39B
Shareholder's equity31.64B
Net tangible assets-29.02B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)16.20B
Capital expenditures (TTM)1.05B
Free cash flow (TTM)15.14B
Dividends paid (TTM)4.47B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity19.82%
Return on Assets6.09%
Return on Invested Capital8.18%
Cash Return on Invested Capital19.76%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open72.66
Daily high72.66
Daily low71.03
Daily Volume9.65M
All-time high79.98
1y analyst estimate80.83
Beta0.44
EPS (TTM)2.83
Dividend per share2.16
Ex-div date30 Jun 2022
Next earnings date26 Oct 2022

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-10.60%-12.18%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-34.57%-11.38%
Avg time to new high41 days12 days
Max time to new high4176 days1805 days
COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
152.23B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees
32200
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.09, marking a -0.86% move from the previous day.
September 30, 2022
In the latest trading session, Bristol Myers Squibb (BMY) closed at $71.71, marking a -0.49% move from the previous day.
September 29, 2022
These businesses might be slightly "boring," but that may just be a good thing in today's market.
September 28, 2022
A look at the shareholders of Bristol-Myers Squibb Company ( NYSE:BMY ) can tell us which group is most powerful. And...
September 28, 2022
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
September 27, 2022
Bristol Myers Squibb Company:
September 26, 2022
Drug companies are facing patent expirations and price pressure, but investors won’t make them pay for those problems just yet.
September 26, 2022
If you want to know who really controls Bristol-Myers Squibb Company ( NYSE:BMY ), then you'll have to look at the...
September 24, 2022
Bristol Myers Squibb (BMY) closed the most recent trading day at $70.71, moving -0.81% from the previous trading session.
September 23, 2022
Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. Instead, today's move appeared to be the result of inves...
September 22, 2022
Next page